Project description:The taxanes, namely Paclitaxel and Docetaxel, are important and widely used cancer chemotherapy drugs in the treatment of invasive and metastatic human breast cancer. Although treatment with the taxanes is beneficial to many patients, drug-responsive tumors in patients with metastatic breast cancer often display resistance to these drugs, either initially or over time following the continued administration of chemotherapy drugs. To investigate the patterns of cross-resistance with the taxane drugs and to identify potential mechanisms of resistance, we generated a series of MDA-MB-231 taxane resistant cell lines. We then used microarrays to determine gene expression differences between sensitive, Docetaxel and Paclitaxel resistant MDA-MB-231 cells. RNA isolated from three independent passages of sensitive, Docetaxel and Paclitaxel resistant cell lines and purified using the Qiagen RNeasy Mini Kit. Total RNA was processed and hybridized to Affymetrix Genechip HU133A arrays.
Project description:The taxanes, namely Paclitaxel and Docetaxel, are important and widely used cancer chemotherapy drugs in the treatment of invasive and metastatic human breast cancer. Although treatment with the taxanes is beneficial to many patients, drug-responsive tumors in patients with metastatic breast cancer often display resistance to these drugs, either initially or over time following the continued administration of chemotherapy drugs. To investigate the patterns of cross-resistance with the taxane drugs and to identify potential mechanisms of resistance, we generated a series of MDA-MB-231 taxane resistant cell lines. We then used microarrays to determine gene expression differences between sensitive, Docetaxel and Paclitaxel resistant MDA-MB-231 cells.
Project description:To identify the extracellular-vesicle-encapsulated miRNAs that are differentially secreted by the MDA-MB-231 metastatic breast cancer cells following treatment with chemotherapy drugs, we profiled the small RNAs (between 17 and 52 nt) isolated from extracellular vesicles by Illumina sequencing. miRNAs that are significantly induced by chemotherapy drugs are identified.
Project description:To identify gene expression changes associated with treatment of EVs from MDA-MB-231 [231] and MCF10A [10A] cells) in NIH3T3 cells, we analyzed RNA isolated from PBS- or EV-treated NIH3T3 cells. Gene expression in NIH3T3 cells treated with EV from MDA-MB-231 cells was compared to cells treated with PBS or EV from MCF10A cells, both of which served as controls in this experiment.
Project description:Low topo2a expression and ER-negative status were predictors of response to doxorubicin, while small tumor size and ER-negative status predicted response to docetaxel. Docetaxel was superior to doxorubicin in triple-negative/basal-like tumors, while no significant differences between these drugs were seen in the remaining intrinsic subtypes Keywords: reference x sample
Project description:MDA-MB-231 breast cancer cells were treated with docosahexaenoic acid with or without doxorubicin chemotherapy Microarrays were used to detail changes in gene expression in the treatments
Project description:To investigate the effects of breast cancer derived EVs on liver metabolism, NSG mice had received 5 weeks of i.v. injections of MCF-10A EVs, MDA-MB-231 EVs or PBS. We then performed gene expression profiling analysis using data obtained from RNA-seq of liver from mice received 5 weeks of i.v. injections of MCF-10A EVs, MDA-MB-231 EVs or PBS.
Project description:Low topo2a expression and ER-negative status were predictors of response to doxorubicin, while small tumor size and ER-negative status predicted response to docetaxel. Docetaxel was superior to doxorubicin in triple-negative/basal-like tumors, while no significant differences between these drugs were seen in the remaining intrinsic subtypes Keywords: reference x sample reference x sample
Project description:To identify gene expression changes associated with treatment of EV that carry high levels of miR-105 (from MDA-MB-231 and MCF10A/miR-105 cells) in human breast tumor derived CAF, we analyzed RNA isolated from PBS- or EV-treated CAF. Gene expression in CAF treated with EV from MDA-MB-231 or MCF10A/miR-105 cells was compared to cells treated with PBS or EV from MCF10A cells, both of which served as controls in this experiment.
Project description:To identify gene expression changes in liver associated with circulating EV that carry high levels of miR-122 (from MDA-MB-231 and MCF10A/miR-122 cells), we analyzed RNA isolated from the liver of PBS- or EV-treated female NOD scid gamma (NSG) mice. Mice had received tail-vein injected EV (or PBS) twice a week for 5 weeks (~10 ug EV per injection). Gene expression in liver from mice treated with EV from MDA-MB-231 or MCF10A/miR-122 cells was compared to cells treated with PBS or EV from MCF10A cells, both of which served as controls in this experiment.